Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Cancer Registry (NCR)

Definition A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives - To measure cancer incidence
- To describe cancer by time, place, persons and disease
- To provide a national database for further epidemiological research
Case definition Target cases are:
- Incident cases by year of diagnosis
- Malignant tumors confirmed by histopathology and/or hematology findings
- Cancers of all sites
Sources of data Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting).
1) The capture system: 
The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms:
- Directly from their clinic; or
- Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients
2) The recapture system: 
The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3).
The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor.
The structure is C##.# M####/##, where:
- C##.# specifies the primary site
- M#### specifies the histology
- /## specifies the behavior and the grade of the tumor
Reporting form NCR reporting form
    4
    ...
ATC Name B/G Ingredients Dosage Form Price
J07BK01 VARICELLA VACCINE LIVE BioTech Varicella-herpes zoster virus (Oka strain), grown in human diploid cells (SV-cell line), live attenuated - Injectable suspension 3,104,276 L.L
A10BH02 VLUDIN G Vildagliptin - 50mg 50mg Tablet 767,910 L.L
C09CA03 VIOSTAN 320 G Valsartan - 320mg 320mg Tablet, film coated 1,338,467 L.L
A10BH02 VLUDIN G Vildagliptin - 50mg 50mg Tablet 767,910 L.L
C09CA03 VIOSTAN 40 G Valsartan - 40mg 40mg Tablet, film coated 526,786 L.L
G04BE09 VERDA G Vardenafil (HCl) - 10mg 10mg Tablet, orally disintegrating 1,023,880 L.L
N05AH03 VAINCOR G Olanzapine - 5mg 5mg Tablet, coated, scored 806,306 L.L
M02AA15 VOLDIC G Diclofenac sodium (diethylamine) - 10mg/g 1% Emulgel 172,012 L.L
J01XA01 VANCO MEDIS 500MG G Vancomycin - 500mg 500mg Injectable powder for solution 998,475 L.L
N05AH03 VAINCOR G Olanzapine - 10mg 10mg Tablet, coated, scored 1,209,458 L.L
J01XA01 VANCOLON G Vancomycin (HCl) - 0.5g 0.5g Injectable lyophilised powder for solution 1,009,226 L.L
J01XA01 VANCOMYCIN HIKMA G Vancomycin (HCl) - 500mg 500mg Injectable powder for solution 998,475 L.L
J01XA01 VANCOMYCINE VIATRIS 500MG G Vancomycin - 500mg 500mg Injectable dry powder for solution 851,399 L.L
J01XA01 VOXIN G Vancomycin (HCl) - 500mg 500mg Injectable powder for solution 546,944 L.L
J01XA01 VANCO MEDIS G Vancomycin - 1g 1g Injectable lyophilisate for solution 1,276,650 L.L
C05CA05 VENOSMIL G Hidrosmin - 200mg 200mg Capsule 976,973 L.L
C05CA05 VENOSMIL G Hidrosmin - 2% 2% Gel 588,603 L.L
C09DA03 VIOSTAN PLUS 80/12.5 G Valsartan - 80mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 547,520 L.L
A11CC05 VITEX D3 G Vitamin D3 - 10,000IU 10,000IU Capsule 447,500 L.L
J01DD04 VERACOL G Ceftriaxone (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 454,219 L.L
A11CC05 VIT-X-FORTE G Vitamin D3 - 10,000IU 10,000IU Capsule 895,895 L.L
C09DA03 VALUSTAR PLUS G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 592,635 L.L
C09DA03 VIOSTAN PLUS 160/12.5 G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 668,082 L.L
B03AD VITEXFER G Folic acid - 1mg, Ascorbic acid - 200mg, Iron ferrous fumarate - 100mg Tablet, film coated 791,523 L.L
C09DA03 VIOSTAN PLUS 160/25 G Valsartan - 160mg, Hydrochlorothiazide - 25mg Tablet, film coated 671,921 L.L
C09DA03 VIOSTAN PLUS 320/25 G Valsartan - 320mg, Hydrochlorothiazide - 25mg Tablet, film coated 1,445,975 L.L
C09DA03 VIOSTAN PLUS 320/12.5 G Valsartan - 320mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 1,411,419 L.L
L01BC07 VAPREZA 100 G Azacitidine - 100mg 100mg Injectable powder for suspension 10,706,993 L.L
A11CC05 VIDROP G Vitamin D3 - 100IU/drop 100IU/drop Drops 346,711 L.L
N07CA01 VASOSERC FORTE G Betahistine dihydrochloride - 16mg 16mg Tablet 944,529 L.L
    4
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025